Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cellular and mitochondrial lipid bilayers are complex, semi-permeable structures composed of phospholipids, sphingolipids, and sterols that define the boundaries of cells and organelles (Source: Molecular Biology of the Cell). These bilayers are not merely passive barriers but are dynamic platforms for signal transduction, vesicular trafficking, and energy conversion, particularly within the mitochondrial inner membrane where the electron transport chain resides. A defining feature of the mitochondrial bilayer is the presence of cardiolipin, a unique phospholipid essential for maintaining the structural integrity of respiratory complexes and preventing the release of pro-apoptotic factors (Source: UniProt). Therapeutic interventions targeting these membranes include antimicrobial agents like daptomycin and polymyxins that exploit differences in lipid composition between pathogens and hosts, as well as novel compounds like elamipretide that stabilize mitochondrial membranes to treat metabolic and degenerative disorders (Source: PubMed, PMID: 25153411). However, the ubiquitous nature of lipid bilayers presents significant challenges for drug design, as non-specific interactions can lead to systemic toxicity, such as the nephrotoxicity associated with certain membrane-disrupting antibiotics (Source: StatPearls, NBK534110). Achieving high selectivity for specific lipid environments remains a primary goal in the development of membrane-active therapeutics.
Drugs targeting these bilayers function through several mechanisms: direct physical disruption leading to pore formation and cytoplasmic leakage (e.g., daptomycin), binding to specific sterols like ergosterol to increase permeability (e.g., amphotericin B), or stabilizing specific phospholipids like cardiolipin to optimize mitochondrial bioenergetics and reduce oxidative stress (e.g., elamipretide).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cellular and mitochondrial lipid bilayers.